Celltrion, Inc. (KRX:068270)

Market Cap	45.77T +21.6%
Revenue (ttm)	4.90T +30.6%
Net Income	1.58T +220.3%
EPS	6,840.22 +226.4%
Shares Out	240.00M
PE Ratio	27.88
Forward PE	31.03
Dividend	714.29 (0.37%)
Ex-Dividend Date	Dec 29, 2025

Volume	375,920
Open	190,700
Previous Close	191,300
Day's Range	187,600 - 190,700
52-Week Range	158,500 - 239,048
Beta	0.30
Analysts	Buy
Price Target	266,031.64 (+39.5%)
Earnings Date	Nov 13, 2026

About Celltrion

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and u...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 2,680
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 068270

Financial Performance

In 2025, Celltrion's revenue was 4.16 trillion, an increase of 17.01% compared to the previous year's 3.56 trillion. Earnings were 1.03 trillion, an increase of 143.58%.

Analyst Summary

According to 23 analysts, the average rating for 068270 stock is "Buy." The 12-month stock price target is ₩266,032, which is an increase of 39.50% from the latest price.

Price Target

₩266,032

(39.50% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 30, 2026

Data Sources Report a data error